Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort

ObjectivesTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.MethodsConsecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Har...

Full description

Saved in:
Bibliographic Details
Published inRheumatic & musculoskeletal diseases open Vol. 9; no. 3; p. e003084
Main Authors Zhao, Yuan, Huang, Can, Qi, Wanting, Zhou, Yangzhong, Zhao, Jiuliang, Wang, Qian, Tian, Xinping, Li, Mengtao, Zhao, Yan, Zeng, Xiaofeng
Format Journal Article
LanguageEnglish
Published England EULAR 01.07.2023
BMJ Publishing Group LTD
BMJ Publishing Group
SeriesOriginal research
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ObjectivesTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.MethodsConsecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.Results362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.ConclusionThe performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately.
AbstractList To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.OBJECTIVESTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.METHODSConsecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.RESULTS362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately.CONCLUSIONThe performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately.
To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS. Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models. 362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal. The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately.
Objectives To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.Methods Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.Results 362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.Conclusion The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately.
ObjectivesTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS.MethodsConsecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models.Results362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal.ConclusionThe performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately.
Author Huang, Can
Tian, Xinping
Li, Mengtao
Zeng, Xiaofeng
Wang, Qian
Qi, Wanting
Zhao, Yan
Zhou, Yangzhong
Zhao, Jiuliang
Zhao, Yuan
AuthorAffiliation Department of Rheumatology and Clinical Immunology , Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education , Beijing , China
AuthorAffiliation_xml – name: Department of Rheumatology and Clinical Immunology , Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education , Beijing , China
Author_xml – sequence: 1
  givenname: Yuan
  orcidid: 0000-0002-9405-6800
  surname: Zhao
  fullname: Zhao, Yuan
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 2
  givenname: Can
  surname: Huang
  fullname: Huang, Can
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 3
  givenname: Wanting
  surname: Qi
  fullname: Qi, Wanting
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 4
  givenname: Yangzhong
  surname: Zhou
  fullname: Zhou, Yangzhong
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 5
  givenname: Jiuliang
  surname: Zhao
  fullname: Zhao, Jiuliang
  email: zjlpumc@sina.com
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 6
  givenname: Qian
  surname: Wang
  fullname: Wang, Qian
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 7
  givenname: Xinping
  orcidid: 0000-0002-1511-7952
  surname: Tian
  fullname: Tian, Xinping
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 8
  givenname: Mengtao
  orcidid: 0000-0003-4252-2889
  surname: Li
  fullname: Li, Mengtao
  email: mengtao.li@cstar.org.cn
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 9
  givenname: Yan
  surname: Zhao
  fullname: Zhao, Yan
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 10
  givenname: Xiaofeng
  surname: Zeng
  fullname: Zeng, Xiaofeng
  organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37507205$$D View this record in MEDLINE/PubMed
BookMark eNp9kstrFTEUxgep2Fr7FwgScOPm2rwmubMSKT4KBTfqNmSSk95cZpIxmVvouv-45z6qbRdd5EHyfT--5JzXzVHKCZrmLaMfGRPqvIw-T5AWnHKxoFTQpXzRnHDaqkXbCXH0YH_cnNW6ppQyKYRm4lVzLHRLNQpOmrvfdojezjEnkgOZVwWATAV8dLuzMXsYKgm5bO_y2OcaKyngNqVAckBiIjbNcVrlimOIU_Sk3iaPWgQhGNJcSW8reII8i3BUAtJvgLi8ymV-07wMdqhwdlhPm19fv_y8-L64-vHt8uLz1aJvJZ1xxpf30roQaBsUV0oEtuSt73xwXDHLuLaSgnZBBCsE41aFIAR4DiCpF6fN5Z7rs12bqcTRlluTbTS7g1yujS1zdAOYloVegaatdGhlckm17xkPnQ5OB9oj69OeNW36EbzDVxY7PII-vklxZa7zjWFULLWSCgkfDoSS_2ygzmaM1cEw2AR5Uw1fSkk73nUdSt8_ka7zpiT8q61KUK1UR1H17mGkf1nui42Cbi9wWIJaIBgX513pMWEcMJrZ9pY59JbZ9pbZ9xZ6xRPvPf551_ne1Y_r_5mfc_wFV7_m-A
CitedBy_id crossref_primary_10_1515_cclm_2024_0114
crossref_primary_10_1016_j_lpmfor_2024_01_017
crossref_primary_10_18273_revmed_v37n2_2024006
Cites_doi 10.1016/j.autrev.2022.103208
10.1016/j.atherosclerosis.2018.09.010
10.1177/0961203307081847
10.1093/rheumatology/keu307
10.1016/j.thromres.2020.10.010
10.1007/s11239-020-02195-4
10.1136/bmjopen-2020-045672
10.1161/CIRCULATIONAHA.107.699579
10.1111/ene.13499
10.1002/art.21149
10.1093/ckj/sfaa188
10.1182/blood-2017-09-805689
10.1093/rheumatology/kes388
10.1111/j.1538-7836.2010.04044.x
10.3389/fimmu.2022.843718
10.1177/0961203320916527
10.1093/rheumatology/41.8.924
10.1136/annrheumdis-2013-204838
10.1016/j.disamonth.2005.02.003
10.1177/0961203317703493
10.1177/0961203320960814
10.1093/rheumatology/kex466
10.1111/j.1538-7836.2006.01753.x
10.1186/s13075-021-02515-w
10.1016/j.semarthrit.2019.04.009
10.1111/1471-0528.15469
10.3389/fimmu.2021.648881
10.1093/rheumatology/kev238
10.1016/s0037-1963(01)90094-0
10.1111/jth.15047
10.1111/bjh.17388
10.1160/TH15-04-0330
10.1016/S0037-1963(01)90094-0
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023
Copyright_xml – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
– notice: 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023
DBID 9YT
ACMMV
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
K9.
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1136/rmdopen-2023-003084
DatabaseName BMJ Open Access Journals
BMJ Journals:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
BMJ Journals
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Publicly Available Content Database

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: ACMMV
  name: BMJ Journals:Open Access
  url: https://journals.bmj.com/
  sourceTypes: Publisher
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2056-5933
ExternalDocumentID oai_doaj_org_article_51fb6e7054ce4014807db12f97fc7f0b
PMC10387646
37507205
10_1136_rmdopen_2023_003084
rmdopen
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS)
  grantid: 2021-I2M-1-005
– fundername: Municipal College Students’ Scientific Research Innovation Program of Beijing
  grantid: S202110023033
– fundername: the Chinese National Key Technology R&D Program, Ministry of Science and Technology
  grantid: 2021YFC2501305
– fundername: National High Level Hospital Clinical Research Funding
  grantid: 2022-PUMCH-A-008; 2022-PUMCH-A-038
– fundername: Beijing Municipal Science & Technology Commission
  grantid: Z201100005520022; Z201100005520023; Z201100005520025; Z201100005520026; Z201100005520027
– fundername: ;
  grantid: 2021YFC2501305
– fundername: ;
  grantid: 2022-PUMCH-A-008; 2022-PUMCH-A-038
– fundername: ;
  grantid: S202110023033
– fundername: ;
  grantid: Z201100005520022; Z201100005520023; Z201100005520025; Z201100005520026; Z201100005520027
– fundername: ;
  grantid: 2021-I2M-1-005
GroupedDBID 53G
5VS
7X7
8FI
8FJ
9YT
ABUWG
ACMMV
ADBBV
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
BENPR
BTFSW
BTHHO
CCPQU
DIK
EBS
EJD
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
HZ~
KQ8
M48
M~E
O9-
OK1
PGMZT
PHGZT
PIMPY
PQQKQ
PROAC
RHI
RMJ
RPM
UKHRP
AAYXX
ADRAZ
CITATION
PHGZM
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-b540t-b5113b4acff05f62663f1825d9dfc261a127a40e7cf3fa3312a6ff33ed2ee40d3
IEDL.DBID M48
ISSN 2056-5933
IngestDate Wed Aug 27 01:31:53 EDT 2025
Thu Aug 21 18:42:24 EDT 2025
Fri Jul 11 01:59:17 EDT 2025
Fri Jul 25 05:37:25 EDT 2025
Thu Apr 03 07:00:46 EDT 2025
Thu Aug 21 00:32:07 EDT 2025
Thu Apr 24 22:56:28 EDT 2025
Thu Apr 24 22:49:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Antiphospholipid Syndrome
Recurrence
Thrombosis
Lupus Erythematosus, Systemic
Language English
License This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b540t-b5113b4acff05f62663f1825d9dfc261a127a40e7cf3fa3312a6ff33ed2ee40d3
Notes Original research
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
YZ and CH are joint first authors.
ORCID 0000-0002-1511-7952
0000-0002-9405-6800
0000-0003-4252-2889
OpenAccessLink https://rmdopen.bmj.com/content/9/3/e003084.full
PMID 37507205
PQID 2843076690
PQPubID 2041888
ParticipantIDs doaj_primary_oai_doaj_org_article_51fb6e7054ce4014807db12f97fc7f0b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10387646
proquest_miscellaneous_2844092999
proquest_journals_2843076690
pubmed_primary_37507205
crossref_citationtrail_10_1136_rmdopen_2023_003084
crossref_primary_10_1136_rmdopen_2023_003084
bmj_journals_10_1136_rmdopen_2023_003084
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
– name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationSeriesTitle Original research
PublicationTitle Rheumatic & musculoskeletal diseases open
PublicationTitleAbbrev RMD Open
PublicationTitleAlternate RMD Open
PublicationYear 2023
Publisher EULAR
BMJ Publishing Group LTD
BMJ Publishing Group
Publisher_xml – name: EULAR
– name: BMJ Publishing Group LTD
– name: BMJ Publishing Group
References Fernandez Mosteirin, Saez Comet, Salvador Osuna (R13) 2017; 26
de Jesús, Sciascia, Andrade (R9) 2019; 126
Barbar, Noventa, Rossetto (R14) 2010; 8
Caprini, Arcelus, Reyna (R16) 2001; 38
Orsi, Lijfering, Geersing (R28) 2021; 193
Sciascia, Sanna, Murru (R4) 2015; 54
Uludağ, Bektaş, Çene (R7) 2021; 51
Jiang, Wang, Jiang (R30) 2021; 23
Miyakis, Lockshin, Atsumi (R17) 2006; 4
Pandor, Tonkins, Goodacre (R24) 2021; 11
Caprini (R15) 2005; 51
Barilaro, Coloma-Bazan, Chacur (R1) 2022; 21
Tang, Hu (R22) 2015; 114
Ramspek, Jager, Dekker (R23) 2021; 14
Sciascia, Sanna, Murru (R3) 2013; 52
Devreese, de Groot, de Laat (R20) 2020; 18
Calvo-Alén, Toloza, Fernández (R29) 2005; 52
Zuily, de Laat, Mohamed (R10) 2015; 54
de Souza, Silva, de Carvalho (R25) 2007; 16
Sayar, Moll, Isenberg (R19) 2021; 198
Erkan, Yazici, Peterson (R26) 2002; 41
Radin, Schreiber, Cecchi (R5) 2018; 25
Cervera, Serrano, Pons-Estel (R2) 2015; 74
Radin, Sciascia, Erkan (R6) 2019; 49
Kearon, Parpia, Spencer (R32) 2018; 131
Di Minno, Scalera, Tufano (R8) 2018; 278
Niznik, Rapoport, Avnery (R12) 2022; 13
Hu, Li, Xie (R21) 2021; 12
Sciascia, Radin, Sanna (R27) 2018; 57
Garcia, Velloso, Martire (R31) 2020; 29
Nascimento, Radin, Gândara (R11) 2020; 29
D’Agostino, Vasan, Pencina (R18) 2008; 117
Nascimento (2025081710461729000_9.3.e003084.11) 2020; 29
Fernandez Mosteirin (2025081710461729000_9.3.e003084.13) 2017; 26
Uludağ (2025081710461729000_9.3.e003084.7) 2021; 51
2025081710461729000_9.3.e003084.28
2025081710461729000_9.3.e003084.29
Caprini (2025081710461729000_9.3.e003084.16) 2001; 38
2025081710461729000_9.3.e003084.26
Garcia (2025081710461729000_9.3.e003084.31) 2020; 29
2025081710461729000_9.3.e003084.25
2025081710461729000_9.3.e003084.23
Niznik (2025081710461729000_9.3.e003084.12) 2022; 13
Radin (2025081710461729000_9.3.e003084.5) 2018; 25
Sciascia (2025081710461729000_9.3.e003084.27) 2018; 57
Hu (2025081710461729000_9.3.e003084.21) 2021; 12
Tang (2025081710461729000_9.3.e003084.22) 2015; 114
Devreese (2025081710461729000_9.3.e003084.20) 2020; 18
2025081710461729000_9.3.e003084.17
2025081710461729000_9.3.e003084.18
2025081710461729000_9.3.e003084.15
Sayar (2025081710461729000_9.3.e003084.19) 2021; 198
2025081710461729000_9.3.e003084.3
2025081710461729000_9.3.e003084.2
2025081710461729000_9.3.e003084.10
2025081710461729000_9.3.e003084.32
2025081710461729000_9.3.e003084.30
2025081710461729000_9.3.e003084.14
Di Minno (2025081710461729000_9.3.e003084.8) 2018; 278
Pandor (2025081710461729000_9.3.e003084.24) 2021; 11
Barilaro (2025081710461729000_9.3.e003084.1) 2022; 21
2025081710461729000_9.3.e003084.6
de Jesús (2025081710461729000_9.3.e003084.9) 2019; 126
2025081710461729000_9.3.e003084.4
References_xml – volume: 21
  start-page: 103208
  year: 2022
  ident: R1
  article-title: Persistence of Antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2022.103208
– volume: 278
  start-page: 60
  year: 2018
  ident: R8
  article-title: The Association of adjusted global Antiphospholipid syndrome score (aGAPSS) with cardiovascular disease in subjects with Antiphospholipid antibodies
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2018.09.010
– volume: 16
  start-page: 782
  year: 2007
  ident: R25
  article-title: Impact of hypertension and Hyperhomocysteinemia on arterial thrombosis in primary Antiphospholipid syndrome
  publication-title: Lupus
  doi: 10.1177/0961203307081847
– volume: 54
  start-page: 134
  year: 2015
  ident: R4
  article-title: The global anti-phospholipid syndrome score in primary APS
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keu307
– volume: 198
  start-page: 213
  year: 2021
  ident: R19
  article-title: Thrombotic Antiphospholipid syndrome: A practical guide to diagnosis and management
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2020.10.010
– volume: 51
  start-page: 466
  year: 2021
  ident: R7
  article-title: Validation of the adjusted global Antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey
  publication-title: J Thromb Thrombolysis
  doi: 10.1007/s11239-020-02195-4
– volume: 11
  year: 2021
  ident: R24
  article-title: Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-045672
– volume: 117
  start-page: 743
  year: 2008
  ident: R18
  article-title: General cardiovascular risk profile for use in primary care: the Framingham heart study
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.107.699579
– volume: 25
  start-page: 320
  year: 2018
  ident: R5
  article-title: The risk of ischaemic stroke in primary Antiphospholipid syndrome patients: a prospective study
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13499
– volume: 52
  start-page: 2060
  year: 2005
  ident: R29
  article-title: Systemic lupus erythematosus in a Multiethnic US cohort (LUMINA). XXV. smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21149
– volume: 14
  start-page: 49
  year: 2021
  ident: R23
  article-title: External validation of Prognostic models: what, Why, how, when and where
  publication-title: Clin Kidney J
  doi: 10.1093/ckj/sfaa188
– volume: 131
  start-page: 2151
  year: 2018
  ident: R32
  article-title: Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism
  publication-title: Blood
  doi: 10.1182/blood-2017-09-805689
– volume: 52
  start-page: 1397
  year: 2013
  ident: R3
  article-title: GAPSS: the global anti-phospholipid syndrome score
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kes388
– volume: 8
  start-page: 2450
  year: 2010
  ident: R14
  article-title: A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2010.04044.x
– volume: 13
  year: 2022
  ident: R12
  article-title: Patterns of recurrent thrombosis in primary Antiphospholipid syndrome-multicenter, real-life long-term follow-up
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.843718
– volume: 29
  start-page: 676
  year: 2020
  ident: R11
  article-title: Global Antiphospholipid syndrome score and anti-Ss2-glycoprotein I domain I for thrombotic risk stratification in Antiphospholipid syndrome: A four-year prospective study
  publication-title: Lupus
  doi: 10.1177/0961203320916527
– volume: 41
  start-page: 924
  year: 2002
  ident: R26
  article-title: A cross-sectional study of clinical thrombotic risk factors and preventive treatments in Antiphospholipid syndrome
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/41.8.924
– volume: 74
  start-page: 1011
  year: 2015
  ident: R2
  article-title: Morbidity and mortality in the Antiphospholipid syndrome during a 10-year period: a Multicentre prospective study of 1000 patients
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204838
– volume: 51
  start-page: 70
  year: 2005
  ident: R15
  article-title: Thrombosis risk assessment as a guide to quality patient care
  publication-title: Dis Mon
  doi: 10.1016/j.disamonth.2005.02.003
– volume: 26
  start-page: 1328
  year: 2017
  ident: R13
  article-title: Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting
  publication-title: Lupus
  doi: 10.1177/0961203317703493
– volume: 29
  start-page: 1866
  year: 2020
  ident: R31
  article-title: Validation of the adjusted global Antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina
  publication-title: Lupus
  doi: 10.1177/0961203320960814
– volume: 57
  start-page: 661
  year: 2018
  ident: R27
  article-title: Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kex466
– volume: 4
  start-page: 295
  year: 2006
  ident: R17
  article-title: International consensus statement on an update of the classification criteria for definite Antiphospholipid syndrome (APS)
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2006.01753.x
– volume: 23
  year: 2021
  ident: R30
  article-title: Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric Antiphospholipid syndrome: a prospective cohort study
  publication-title: Arthritis Res Ther
  doi: 10.1186/s13075-021-02515-w
– volume: 49
  start-page: 464
  year: 2019
  ident: R6
  article-title: The adjusted global Antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2019.04.009
– volume: 126
  start-page: 656
  year: 2019
  ident: R9
  article-title: Factors associated with first thrombosis in patients presenting with obstetric Antiphospholipid syndrome (APS) in the APS Alliance for clinical trials and international networking clinical database and repository: a retrospective study
  publication-title: BJOG
  doi: 10.1111/1471-0528.15469
– volume: 12
  start-page: 648881
  year: 2021
  ident: R21
  article-title: Comparison of different test systems for the detection of Antiphospholipid antibodies in a Chinese cohort
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.648881
– volume: 54
  start-page: 2071
  year: 2015
  ident: R10
  article-title: Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective Multicentre cohort study
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kev238
– volume: 38
  start-page: 12
  issue: 2 Suppl 5
  year: 2001
  ident: R16
  article-title: Effective risk stratification of surgical and Nonsurgical patients for venous thromboembolic disease
  publication-title: Semin Hematol
  doi: 10.1016/s0037-1963(01)90094-0
– volume: 18
  start-page: 2828
  year: 2020
  ident: R20
  article-title: Guidance from the scientific and standardization Committee for lupus anticoagulant/Antiphospholipid antibodies of the International society on thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation
  publication-title: Journal of Thrombosis and Haemostasis
  doi: 10.1111/jth.15047
– volume: 193
  start-page: 1194
  year: 2021
  ident: R28
  article-title: Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study
  publication-title: Br J Haematol
  doi: 10.1111/bjh.17388
– volume: 114
  start-page: 901
  year: 2015
  ident: R22
  article-title: Ethnic diversity in the Genetics of venous thromboembolism
  publication-title: Thromb Haemost
  doi: 10.1160/TH15-04-0330
– ident: 2025081710461729000_9.3.e003084.32
  doi: 10.1182/blood-2017-09-805689
– volume: 126
  start-page: 656
  year: 2019
  ident: 2025081710461729000_9.3.e003084.9
  article-title: Factors associated with first thrombosis in patients presenting with obstetric Antiphospholipid syndrome (APS) in the APS Alliance for clinical trials and international networking clinical database and repository: a retrospective study
  publication-title: BJOG
  doi: 10.1111/1471-0528.15469
– ident: 2025081710461729000_9.3.e003084.10
  doi: 10.1093/rheumatology/kev238
– volume: 57
  start-page: 661
  year: 2018
  ident: 2025081710461729000_9.3.e003084.27
  article-title: Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kex466
– ident: 2025081710461729000_9.3.e003084.4
  doi: 10.1093/rheumatology/keu307
– volume: 51
  start-page: 466
  year: 2021
  ident: 2025081710461729000_9.3.e003084.7
  article-title: Validation of the adjusted global Antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey
  publication-title: J Thromb Thrombolysis
  doi: 10.1007/s11239-020-02195-4
– ident: 2025081710461729000_9.3.e003084.26
  doi: 10.1093/rheumatology/41.8.924
– ident: 2025081710461729000_9.3.e003084.28
  doi: 10.1111/bjh.17388
– ident: 2025081710461729000_9.3.e003084.18
  doi: 10.1161/CIRCULATIONAHA.107.699579
– volume: 21
  start-page: 103208
  year: 2022
  ident: 2025081710461729000_9.3.e003084.1
  article-title: Persistence of Antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2022.103208
– volume: 25
  start-page: 320
  year: 2018
  ident: 2025081710461729000_9.3.e003084.5
  article-title: The risk of ischaemic stroke in primary Antiphospholipid syndrome patients: a prospective study
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13499
– ident: 2025081710461729000_9.3.e003084.14
  doi: 10.1111/j.1538-7836.2010.04044.x
– volume: 29
  start-page: 1866
  year: 2020
  ident: 2025081710461729000_9.3.e003084.31
  article-title: Validation of the adjusted global Antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina
  publication-title: Lupus
  doi: 10.1177/0961203320960814
– ident: 2025081710461729000_9.3.e003084.6
  doi: 10.1016/j.semarthrit.2019.04.009
– ident: 2025081710461729000_9.3.e003084.2
  doi: 10.1136/annrheumdis-2013-204838
– volume: 29
  start-page: 676
  year: 2020
  ident: 2025081710461729000_9.3.e003084.11
  article-title: Global Antiphospholipid syndrome score and anti-Ss2-glycoprotein I domain I for thrombotic risk stratification in Antiphospholipid syndrome: A four-year prospective study
  publication-title: Lupus
  doi: 10.1177/0961203320916527
– ident: 2025081710461729000_9.3.e003084.15
  doi: 10.1016/j.disamonth.2005.02.003
– ident: 2025081710461729000_9.3.e003084.25
  doi: 10.1177/0961203307081847
– volume: 12
  start-page: 648881
  year: 2021
  ident: 2025081710461729000_9.3.e003084.21
  article-title: Comparison of different test systems for the detection of Antiphospholipid antibodies in a Chinese cohort
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.648881
– volume: 11
  year: 2021
  ident: 2025081710461729000_9.3.e003084.24
  article-title: Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-045672
– volume: 26
  start-page: 1328
  year: 2017
  ident: 2025081710461729000_9.3.e003084.13
  article-title: Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting
  publication-title: Lupus
  doi: 10.1177/0961203317703493
– volume: 13
  year: 2022
  ident: 2025081710461729000_9.3.e003084.12
  article-title: Patterns of recurrent thrombosis in primary Antiphospholipid syndrome-multicenter, real-life long-term follow-up
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.843718
– volume: 18
  start-page: 2828
  year: 2020
  ident: 2025081710461729000_9.3.e003084.20
  article-title: Guidance from the scientific and standardization Committee for lupus anticoagulant/Antiphospholipid antibodies of the International society on thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation
  publication-title: Journal of Thrombosis and Haemostasis
  doi: 10.1111/jth.15047
– volume: 278
  start-page: 60
  year: 2018
  ident: 2025081710461729000_9.3.e003084.8
  article-title: The Association of adjusted global Antiphospholipid syndrome score (aGAPSS) with cardiovascular disease in subjects with Antiphospholipid antibodies
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2018.09.010
– volume: 38
  start-page: 12
  issue: 2 Suppl 5
  year: 2001
  ident: 2025081710461729000_9.3.e003084.16
  article-title: Effective risk stratification of surgical and Nonsurgical patients for venous thromboembolic disease
  publication-title: Semin Hematol
  doi: 10.1016/S0037-1963(01)90094-0
– ident: 2025081710461729000_9.3.e003084.23
  doi: 10.1093/ckj/sfaa188
– volume: 198
  start-page: 213
  year: 2021
  ident: 2025081710461729000_9.3.e003084.19
  article-title: Thrombotic Antiphospholipid syndrome: A practical guide to diagnosis and management
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2020.10.010
– ident: 2025081710461729000_9.3.e003084.30
  doi: 10.1186/s13075-021-02515-w
– ident: 2025081710461729000_9.3.e003084.17
  doi: 10.1111/j.1538-7836.2006.01753.x
– ident: 2025081710461729000_9.3.e003084.3
  doi: 10.1093/rheumatology/kes388
– ident: 2025081710461729000_9.3.e003084.29
  doi: 10.1002/art.21149
– volume: 114
  start-page: 901
  year: 2015
  ident: 2025081710461729000_9.3.e003084.22
  article-title: Ethnic diversity in the Genetics of venous thromboembolism
  publication-title: Thromb Haemost
  doi: 10.1160/TH15-04-0330
SSID ssj0001433713
Score 2.2390263
Snippet ObjectivesTo validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict...
To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis...
Objectives To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
bmj
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e003084
SubjectTerms Adult
Anemia
Antibodies
Anticoagulants
Antiphospholipid Syndrome
Antiphospholipid Syndrome - complications
Antiphospholipid Syndrome - diagnosis
Autoimmune diseases
Autoimmunity
Calibration
Female
Heart attacks
Humans
Hypertension
Ischemia
Lupus
Lupus Erythematosus, Systemic
Male
Medical imaging
Medical prognosis
Middle Aged
Morbidity
Pregnancy
Prospective Studies
Pulmonary embolisms
Recurrence
Regression analysis
Risk Assessment
Thrombocytopenia
Thromboembolism
Thrombosis
Thrombosis - diagnosis
Thrombosis - epidemiology
Thrombosis - etiology
Transient ischemic attack
Venous Thrombosis - diagnosis
Venous Thrombosis - epidemiology
Venous Thrombosis - etiology
Young Adult
SummonAdditionalLinks – databaseName: BMJ Open Access Journals
  dbid: 9YT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB61Rap6QbxJKchIHDiQbhI79voIiKpCKqcWlVPkODYN6iarJP0F_PHOOMmWRajisKtV7Mwm88jM2JlvAN5pqbTXvIqNzzBBWS4F2py1-CunTS_BuaEC57Nv8vRCfL3ML3cgmWthulVFbaOOy9WvsaKBMJqaYaEXfOECuIo4poXpXXhArUlIj_WP87tVFSSOadcEL5RyOROMqU14PBI4gH2OjlJl1LNuF_9pyycF6P5_xZt_vzb5hx86eQQPpwCSfRwl_hh2XPME9s-mLfKn8Ps7RtZjoyTWejagrBxbdzQejoXWNz3DWJXG2lXZ9nXPOlp2D4V_rG4YcrteX7U9fq7rdV2xGdeATTCsPSPvVzGkZ5B4O9drMuq32w3P4OLky_nn03jqtBCXGLEN-I28KoWx3ie5xxxHco-JR17pylvMsUyaKSMSp6zn3nCeZkZ6z7mrMudEUvHnsNe0jXsJTNtUWGkymRstqMZLJdI6oZFtCc-XPIL3yPFispS-CEkIl8Ukp4LkVIxyiiCbxVLYCbGcGmdc33_Sh81J6xGw4_7pn0jem6mEth0OtN3PYjLeIk99KZ3C6BbvhJZgE1WVaea18lb5pIzgaNaWuxtDv4_PTyl1EsHbzTAaL-3ImMa1N2EO5tcYEegIXozKtbmSWUUjWG6p3dalbo809VUACCfQeyWFPPx_Xr-Cg9FC6EXkI9gbuhv3GsOtoXwTLOwWNFUoqg
  priority: 102
  providerName: BMJ Publishing Group Ltd
– databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hHhAXxJtAQUbiwIGoSezY6yMgqgqpnCjqLXL8UIO6ySpJfwF_nBnHu-wiVC4cEkWxkzjz8Mz48Q3AWy2VDpq73IQKA5TVSqDOWYtXNU16Cc4NbXA-_yrPLsSXy_pyL9UXrQlb4IEXwp3UZWilV-hZWC9o-KtQri2roFWwKhQt9b5o8_aCqTi6gh_B8CvBDJVcnoxrR_mockoXnkeUFoHmpF3_ODBIEbf_b87mn2sm94zQ6QO4n7xH9mFp9UO44_tHcPc8zY8_hp_f0a1esiSxIbAZGeXZZqTyeC_mvZkYOqpUNqzbYeomNtKYe9z1x7qeIam7zdUw4XHdbTrHtqAGLGGwToxMn2P4PoMvH7abNRkl2x3nJ3Bx-vnbp7M8pVnIW3TXZjwjgVphbAhFHTDAkTxg1FE77YLFAMuUlTKi8MoGHgznZWVkCJx7V3lkieNP4agfev8cmLalsNJUsjZa0AYvVUhkm0ayFbxe8QzeIcWbpCZTEyMQLpvEnIaY0yzMyaDasqWxCa6csmZc3_7Q-91DmwWt4_bqH4nfu6oEtR1voAA2SQCbfwlgBsdbafn9Y2j0sfOUUhcZvNkVo-bSdIzp_XAT62Bwje6AzuDZIly7lnB05FRV1BmsDsTuoKmHJX13FdHBCfFeSSFf_I-fewn3FoWh9cnHcDSPN_4VemFz-zoq3C9OUjIa
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkRAXxJvAgozEgQPRJrFjNycEiNUKaTmxqLfI8YPNahuHJPsL-OPMOE5LEeqhVRU7qeOZsb8Z298Q8rYSsnIVM6lyBTgoqxUHm9MafpW46MUZU3jA-fybOLvgX9flOgbcxritchkTw0BtvMYY-QkMo6COApy5D_2vFLNG4epqTKFxm9xB6jLUarmWuxgL_BU4YZFsKGfiZNgYzEqVYtLwNHC1cJhUms3V3rQU2Pv_Bzn_3Tn511R0-oDcjxiSfpyF_pDcst0jcvc8rpI_Jr9_ALiecyVR7-gE4rK0H7A8XAvZb0YKcBXL_KbxYzvSASPv4ewfbTsKHd72l36Ez3Xbt4Yu1AY0MrGOFCdAQ-F5Ch7ulyObFFPuDtMTcnH65fvnszQmW0gbAG0TfEMHNVxp57LSgZsjmAPfozSVcRrcLJUXUvHMSu2YU4zlhRLOMWZNYS3PDHtKjjrf2eeEVjrnWqhClKrieMxLZkJbXkG3ZaxcsYS8gx6vo7GMdfBDmKijcGoUTj0LJyHFIpZaR9JyzJ1xffim99ub-pmz43D1TyjvbVUk3A4X_PCzjvZbl7lrhJUAcOFNMAqbSdPkhauk09JlTUKOF23ZvdhOZxPyZlsM9ouLMqqz_ibUARcbQEGVkGezcm1bwgDOySIrE7LaU7u9pu6XdO1l4AhH3nspuHhxuF0vyb3ZFHD_8TE5moYb-wpQ1tS8Dqb0BxoUKZA
  priority: 102
  providerName: ProQuest
Title Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
URI https://rmdopen.bmj.com/content/9/3/e003084.full
https://www.ncbi.nlm.nih.gov/pubmed/37507205
https://www.proquest.com/docview/2843076690
https://www.proquest.com/docview/2844092999
https://pubmed.ncbi.nlm.nih.gov/PMC10387646
https://doaj.org/article/51fb6e7054ce4014807db12f97fc7f0b
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED-tmzTtBfFNxqiMxAMPFJLYsesHhLZp04TUCaF1Kk-Rk9gsqE26pJPgmX-cs-MUirY9NK3ijya-u9ydHf9-AG8kF9JIWoyUiTFBGY8Z2lye46_ELnoxSpXd4Dw552dT9nmWzLagZ0X1A9jemtpZPqlpM3__8_rXJzT4j56R5EOzKGzRyDKBjxwACxvADromYSkNJj7ed5Mu-N-YlXn0oTva7sEuRT8qYktpN8gWPzZclkP2vy0c_f-tyn_c1OlDeODjS3LYKcQj2NLVY9id-BX0J_D7EgPvjkeJ1IasUJSaLBtb7s45ZpyWYChry-pFVrdlSxo7K-_2BZKyIiiMcnlVt_iZl8uyID3sAfEorS2xzrEg2J_Czut-OyexdLzN6ilMT08ujs9GnohhlGFAt8IjjlXGVG5MmBhMgTg1mJckhSxMjimYimKhWKhFbqhRlEax4sZQqotYaxYW9BlsV3WlXwCRecRyrmKeKMnsFjAR8lwzicMW0mRMA3iLI572epC6HIXy1MsptXJKOzkFEPdiSXMPaG55Neb3N3q3brTs8Dzur35k5b2uasG43Ym6-Z56206TyGRcCwx-8U7sDG0oiiyKjRQmFybMAjjoteXvjWFYgI9XzmUYwOt1Mdq2XbBRla5vXB1MvzFgkAE875RrfSW9igYw3lC7jUvdLKnKK4cfbjHxBWd8_85OX8JeZxD2teQD2F41N_oVBl-rbAgDMRN4lN8uhrBzeDyZXOL30cn5l69DN6ExdCb3B09vNAw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4lkCBYwEEgeiJrFjbw4I8aq2tNtTi_YWHMemQd0kJKkQZ_4Pv5EZJ9llEdpbD4mi2LHszOsbP2YIeZ4ImdiE5b6yETgokwkHmdManmJc9OKMKTzgPDsW01P-aR7Pt8jv8SwMbqscdaJT1HmlcY58D9QosKMAZ-5N_d3HrFG4ujqm0OjZ4tD8_AEuW_v64APQ90UU7X88eT_1h6wCfgbopIN7GLKMK21tEFvA84JZANlxnuRWgz-hwkgqHhipLbOKsTBSwlrGTB4Zw4OcQbtXyFUwvAE6e3IuV3M6MDRw-obgRiETe80ixyxYPiYp911sGA5GLFt8WzODLlvA_yDuvzs1_zJ9-7fIzQGz0rc9k90mW6a8Q67NhlX5u-TXZwDzfW4mWlnaAXsYWjdY7t65bDstBXiMZdUiq9qipQ3O9LuzhrQoKRC4qM-qFq7zoi5yOoZSoEPk15aiwc0ptKeg8Wo8IkoxxW_T3SOnl0KG-2S7rErzgNBEh1wLFYlYJRyPlclAaMMT-G0BiyfMIy_hj6eDcLap83uYSAfipEictCeOR6KRLKkegqRjro7zzR-9Wn5U9zFCNld_h_ReVsUA3-5F1XxNB32RxqHNhJEAqGEkOOsbyDwLI5tIq6UNMo_sjtyyGthKRjzybFkM-gIXgVRpqgtXB1x6ACGJR3Z65lr2hAF8lFEQe2SyxnZrXV0vKYszF5Mc4-xLwcXDzf16Sq5PT2ZH6dHB8eEjcqMXC9z7vEu2u-bCPAaE12VPnFhR8uWy5fgPUHtnEw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVqq4IN6kFDASSByINokde3NAiNKuWkpXFaKot-A4Nk3VTZZkK8SZf8WvYyZxdlmE9tZDoih2LDvz8De2Z4aQF4mQiU1Y7isbgYEyGnGQOa3hKcZNL86YQgfn44k4OOUfzuKzDfK794XBY5W9TmwVdV5pXCMfghoFdhRgzA2tOxZxsjd-O_vuYwYp3Gnt02l0LHJkfv4A8615c7gHtH4ZReP9z-8PfJdhwM8AqczhHoYs40pbG8QWsL1gFgB3nCe51WBbqDCSigdGasusYiyMlLCWMZNHxvAgZ9DuDbIp0SoakM3d_cnJp-UKDwwUTEAX6ihkYlhPc8yJ5WPKcr-NFMNhSsumFyuTYps74H-A999zm39NhOPb5JZDsPRdx3J3yIYp75KtY7dHf4_8-gLQvsvURCtL58Ashs5qLG_ftbl3GgpgGcuqaVY1RUNrXPdvPQ9pUVIgdzE7rxq4LotZkdM-sAJ1cWAbitNvTqE9BY1XvcMoxYS_9fw-Ob0WQjwgg7IqzSNCEx1yLVQkYpVwdDKTgdCGJ_DbAhaPmEdewR9Pnag2aWsFMZE64qRInLQjjkeiniypdiHTMXPH5fqPXi8-mnURQ9ZX30V6L6piuO_2RVV_S532SOPQZsJIgNcwElwDDmSehZFNpNXSBplHdnpuWQ5sKTEeeb4oBu2BW0KqNNVVWwcMfIAkiUcedsy16AkDMCmjIPbIaIXtVrq6WlIW522Ecoy6LwUX2-v79YxsgQynHw8nR4_JzU4q8CD0DhnM6yvzBODePHvq5IqSr9ctyn8A7edsrg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+three+prediction+models+for+thrombosis+recurrence+in+antiphospholipid+syndrome+patients+based+on+a+prospective+cohort&rft.jtitle=Rheumatic+%26+musculoskeletal+diseases+open&rft.au=Zhao%2C+Yuan&rft.au=Huang%2C+Can&rft.au=Qi%2C+Wanting&rft.au=Zhou%2C+Yangzhong&rft.date=2023-07-01&rft.eissn=2056-5933&rft.volume=9&rft.issue=3&rft_id=info:doi/10.1136%2Frmdopen-2023-003084&rft_id=info%3Apmid%2F37507205&rft.externalDocID=37507205
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-5933&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-5933&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-5933&client=summon